ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. Leading healthcare companies have licensed rights to use ImmunoGen's technology to develop novel anticancer therapies, and Roche's marketed product, Kadcyla, utilizes ImmunoGen's ADC technology.
Company Growth (employees)
Waltham, US
Size (employees)
308 (est)-2%
ImmunoGen was founded in 1981 and is headquartered in Waltham, US

Key People at ImmunoGen

Stephen C. McCluski

Stephen C. McCluski


ImmunoGen Office Locations

ImmunoGen has offices in Waltham, Norwood and Brentwood
Waltham, US (HQ)
830 Winter St
Norwood, US
333 Providence Hwy

ImmunoGen Data and Metrics

ImmunoGen Financial Metrics

ImmunoGen's revenue was reported to be $60 m in FY, 2016 which is a 30% decrease from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

60 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

(144.8 m)

EBIT (FY, 2016)

(125 m)

Market capitalization (24-May-2017)

454.8 m

Closing share price (24-May-2017)


Cash (30-Jun-2016)

245 m
ImmunoGen's current market capitalization is $454.8 m.
Numbers are in $, USDFY, 2014FY, 2015FY, 2016


59.9 m85.5 m60 m

Revenue growth, %


Operating expense total

131.4 m140 m185 m


(71.5 m)(54.5 m)(125 m)

EBIT margin, %


Net Income

(71.4 m)(60.7 m)(144.8 m)
Numbers are in $, USDFY, 2014FY, 2015FY, 2016


142.3 m278.1 m245 m

Accounts Receivable

1.9 m5.1 m883 k


3 m2.9 m907 k

Current Assets

150.8 m292.2 m254.8 m


14.3 m16.3 m22.7 m

Total Assets

165.3 m313.8 m287.1 m

Accounts Payable

4.8 m8.1 m11.5 m

Current Liabilities

21.3 m35.8 m61.4 m

Additional Paid-in Capital

723 m743.1 m770.5 m

Retained Earnings

(648.1 m)(708.9 m)(853.7 m)

Total Equity

75.7 m35.1 m

Financial Leverage

2.2 x8.9 x
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Net Income

(71.4 m)(60.7 m)(144.8 m)

Depreciation and Amortization

4.6 m5.5 m5.3 m

Accounts Receivable

(1.9 m)(3.2 m)4.2 m


(2.2 m)15 k2 m

Accounts Payable

321 k3.3 m2.6 m

Cash From Operating Activities

(53.7 m)(55.3 m)(124.5 m)

Purchases of PP&E

(10.4 m)

Cash From Investing Activities

(8.2 m)(7.4 m)(10.4 m)

Cash From Financing Activities

9.1 m198.6 m101.8 m
Numbers are in $, USDY, 2016


189.3 k

ImmunoGen Market Value History

ImmunoGen Job Categories

ImmunoGen Median Salaries

Source: 17 public H-1B filings from ImmunoGen

ImmunoGen Online and Social Media Presence

ImmunoGen Company Life and Culture

You may also be interested in